Mr. Broshy assists Tailwind in sourcing, evaluating and performing due diligence on healthcare opportunities. Mr. Broshy serves as the Chairman of the Board of Directors of DermaRite.
Mr. Broshy has over 30 years of management experience within the healthcare industry, including serving as Chief Executive Officer and Chairman of inVentiv Health, Inc. for over a decade. Mr. Broshy took inVentiv public in 1999, and under his leadership transformed the company into the leading provider of clinical and commercialization services to the global pharmaceutical and biotechnology industries, growing revenue from $215 million in 2002 to $1.1 billion in 2008. In 2010, Mr. Broshy led the company's $1.2 billion go-private transaction. Subsequent to inVentiv Health, Mr. Broshy partnered with a number of private equity firms to evaluate healthcare investment opportunities.
Prior to inVentiv Health, Mr. Broshy spent 14 years at The Boston Consulting Group, Inc. (BCG), where he was responsible for the firm's healthcare practice across the Americas. At BCG, Mr. Broshy consulted widely with senior executives from a number of major global pharmaceutical manufacturers, managed care organizations, and academic medical centers, leading solutions on a broad range of strategic, organizational and operational initiatives. Mr. Broshy also served as President and Chief Executive Officer of Coelacanth Corporation, a privately-held biotechnology company.
Mr. Broshy currently serves as Chairman of the Board of ERT, as well on the Board of Directors of Magellan Health (Nasdaq: MGLN), Theravance Biopharma (Nasdaq: TBPH), and FDNA. He previously served on the Board of Directors of a number of healthcare companies, including inVentiv Health, Neurogen (Nasdaq: NRGN), ikaSystems, Virtual Radiologic, and HeartFlow. He also serves on the MIT Corporation Board and on several MIT Visiting Committees.
Mr. Broshy received an MBA from Harvard Business School, an MS from Stanford University, and a BS from the Massachusetts Institute of Technology.